Extended-spectrum β-Lactamases-producing Klebsiella pneumoniae and Escherichia coli: Clinical Distribution and Antibiotic Resistance

OBJECTIVE To study the clinical distribution and the drug resistance of extended-spectrum β-lactamases (ESBLs) producing Klebsiella pneumoniae and Escherichia coli. METHODS The clinical isolates were identified by VITEK-60 of Bio-Merieux of France. K-B agar diffusion method and confirmed test were used to detect the drug resistance of ESBLs-producing K. pneumoniae and E. coli. RESULTS The incidence of ESBLs was 52.8% in E. coli and 63.5% in K. pneumoniae. E. coli was mostly isolated from urine (22.1%). The second was isolated from pus/wound (11.7%). Majority strains were isolated from surgical and pediatric wards. K. pneumoniae was mostly isolated from sputum and throat swab (37.8%), 21.8% from neonate ward and 16% from child ICU. CONCLUSIONS To cure infections caused by ESBLs-producing K. pneumoniae and E. coli, imipenem is the best choice and piperacillin/tazobactam is the second choice.